vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
vTv Therapeutics (Nasdaq: VTVT) announced its participation in the INNODIA Symposium at the EASD 61st Annual Meeting, where it will present research on two investigational small molecules for type 1 diabetes (T1D). Dr. Carmen Valcarce, EVP and CSO, will present new preclinical data on TTP-RA, an oral RAGE antagonist being evaluated for T1D prevention in combination with an anti-CD3 antibody.
The presentation will include data demonstrating TTP-RA's ability to restore glucose homeostasis and modulate immune responses. Additionally, updates will be shared on cadisegliatin, their first-in-class oral glucokinase activator currently in Phase 3 trials (CATT1) as an adjunctive therapy for T1D. The company is actively seeking strategic partnerships to advance TTP-RA development.
vTv Therapeutics (Nasdaq: VTVT) ha annunciato la sua partecipazione allo Symposium INNODIA durante l’EASD 61st Annual Meeting, dove presenterà ricerche su due piccole molecole sperimentali per il diabete di tipo 1 (T1D). Dr. Carmen Valcarce, EVP e CSO, presenterà nuovi dati preclinici su TTP-RA, un antagonista orale di RAGE valutato per la prevenzione del T1D in combinazione con un anticorpo anti-CD3.
La presentazione includerà dati che dimostrano la capacità di TTP-RA di ripristinare l’omeostasi della glicemia e di modulare le risposte immunitarie. Inoltre, saranno condivisi aggiornamenti su cadisegliatin, il loro attivatore orale della glucokinasi di prima classe attualmente in stadi di Fase 3 (CATT1) come terapia adiuvante per il T1D. L’azienda è attivamente alla ricerca di partnership strategiche per avanzare lo sviluppo di TTP-RA.
vTv Therapeutics (Nasdaq: VTVT) anunció su participación en el Symposium INNODIA en la 61.ª Reunión Anual de la EASD, donde presentará investigaciones sobre dos moléculas pequeñas en investigación para la diabetes tipo 1 (T1D). La Dra. Carmen Valcarce, EVP y CSO, presentará nuevos datos preclínicos sobre TTP-RA, un antagonista oral de RAGE que se está evaluando para la prevención de T1D en combinación con un anticuerpo anti-CD3.
La presentación incluirá datos que demuestran la capacidad de TTP-RA para restablecer la homeostasis de la glucosa y modular las respuestas inmunes. Además, se compartirán actualizaciones sobre cadisegliatin, su activador oral de glucocinasa de primera clase actualmente en ensayos de fase 3 (CATT1) como terapia adyuvante para T1D. La empresa busca activamente asociaciones estratégicas para avanzar en el desarrollo de TTP-RA.
vTv Therapeutics (나스닥: VTVT)은 INNODIA 심포지엄에 참가한다고 발표했으며, EASD 61차 연례 회의에서 1형 당뇨(T1D)를 위한 두 가지 연구용 소분자에 대한 연구를 발표합니다. Dr. Carmen Valcarce EVP 겸 CSO가 TTP-RA에 대한 새로운 전임상 데이터를 발표할 예정이며, 이는 항-CD3 항체와의 병용으로 T1D 예방을 위한 구강 RAGE 길항제입니다.
발표에는 TTP-RA가 포도당 항상성을 회복하고 면역 반응을 조절하는 능력을 보여주는 데이터가 포함될 것입니다. 또한 cadisegliatin에 대한 업데이트도 공유되며, 이는 3상(CATT1) 단계에 현재 있는 차세대 구강 글루코키나아제 활성화제이며 T1D의 보조 치료제로 개발 중입니다. 회사는 TTP-RA 개발을 추진하기 위한 전략적 파트너십을 적극 모색하고 있습니다.
vTv Therapeutics (Nasdaq: VTVT) a annoncé sa participation au Symposium INNODIA lors de la 61e Réunion annuelle de l’EASD, où elle présentera des recherches sur deux petites molécules investigatrices pour le diabète de type 1 (T1D). Dr. Carmen Valcarce, EVP et CSO, présentera de nouveaux data précliniques sur TTP-RA, un antagoniste oral de RAGE évalué pour la prévention du T1D en association avec un anticorps anti-CD3.
La présentation comportera des données démontrant la capacité de TTP-RA à restaurer l’homéostasie de la glucose et à moduler les réponses immunes. Des mises à jour sur cadisegliatin, leur activateur oral de glucokinase de première classe, actuellement en essais de phase 3 (CATT1) comme thérapie adjuvante pour le T1D, seront également partagées. L’entreprise recherche activement des partenariats stratégiques pour faire progresser le développement de TTP-RA.
vTv Therapeutics (Nasdaq: VTVT) hat seine Teilnahme am INNODIA-Symposium auf der 61. Jahrestagung der EASD angekündigt, wo sie Forschungen zu zwei experimentellen kleinen Molekülen für Typ-1-Diabetes (T1D) vorstellen wird. Dr. Carmen Valcarce, EVP und CSO, wird neue präklinische Daten zu TTP-RA präsentieren, einem oralen RAGE-Antagonisten, der auf die Prävention von T1D in Kombination mit einem Anti-CD3-Antikörper untersucht wird.
Die Präsentation wird Daten enthalten, die die Fähigkeit von TTP-RA zeigen, die Glukosehomöostase wiederherzustellen und Immunreaktionen zu modulieren. Außerdem werden Updates zu cadisegliatin gegeben, dem ersten oralen Glucokinase-Aktivator in der Klasse, aktuell in Phase-3-Studien (CATT1) als adjunktive Therapie für T1D. Das Unternehmen sucht aktiv nach strategischen Partnerschaften, um die Entwicklung von TTP-RA voranzubringen.
vTv Therapeutics (ناسداك: VTVT) أعلنت مشاركتها في ندوة INNODIA خلال اجتماع EASD السنوي الحادي والستين، حيث ستعرض أبحاث عن جزيئين صغيرين قيد الدراسة لمرض السكري من النوع 1 (T1D). ستقدم الدكتورة كارمن فالكارسي، نائب الرئيس التنفيذي للشؤون العلمية وكبير مسؤولي العلماء، بيانات جديدة قبل السريرية عن TTP-RA، وهو مثبط رِيج جار Oral يُقيَّم للوقاية من T1D بالتوازي مع جسم مضاد Anti-CD3.
سيشمل العرض بيانات تبيّن قدرة TTP-RA على استعادة التوازن الغذائي وتنظيم الاستجابات المناعية. كما ستتم مشاركة تحديثات حول cadisegliatin، مُنشِّط الغلوكوكيناتاز الفموي من فئة الأولى والذي لا يزال في المرحلة 3 (CATT1) كعلاج مساعد لـ T1D. تسعى الشركة بنشاط إلى شراكات استراتيجية لدفع تطوير TTP-RA قدمًا.
vTv Therapeutics（纳斯达克：VTVT） 宣布将参加 INNODIA 研讨会，地点位于 EASD 第61届年会上。他们将展示两种用于1型糖尿病（T1D）的在研小分子研究。Carmen Valcarce 博士，执行副总裁兼首席科学官，将介绍
此次报告将包含显示TTP-RA能够恢复葡萄糖稳态并调节免疫应答的数据。此外，还将更新其首款同类口服葡萄糖激酶激活剂cadisegliatin，目前处于III期（CATT1）临床阶段，作为T1D的辅助治疗。公司正在积极寻求战略合作伙伴关系，以推动TTP-RA的开发。
- None.
- None.
Company to share new independent research on TTP-RA, vTv’s oral RAGE antagonist
HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational small molecules for type 1 diabetes (T1D) at the INNODIA Symposium during the European Association for the Study of Diabetes (EASD) 61st Annual Meeting. INNODIA is an international non-for-profit organization that aims to accelerate the development of therapies to prevent and cure T1D.
Carmen Valcarce, Ph.D., Executive Vice President and Chief Scientific Officer of vTv Therapeutics, will present new preclinical data from independent, researcher-run studies of TTP-RA conducted by Professor Josephine Forbes, Ph.D. of the University of Queensland. TTP-RA is vTv’s oral RAGE (Receptor for Advanced Glycation End-products) antagonist, being evaluated in combination with an anti-CD3 antibody for the prevention of T1D. vTv is actively seeking strategic partnerships to advance TTP-RA development.
At the INNODIA Symposium, Dr. Valcarce will share details of TTP-RA, including preclinical data that show TTP-RA’s ability to restore glucose homeostasis and modulate immune responses. Importantly, she will also share an update on the development of cadisegliatin, a potential first-in-class oral glucokinase activator adjunctive therapy in the ongoing Phase 3 study for the treatment for T1D (CATT1).
“While cadisegliatin advances through Phase 3 development as a potential novel adjunctive therapy for T1D patients, this preclinical data with TTP-RA represents an exciting research opportunity to potentially prevent T1D onset,” said Dr. Valcarce. “Our unique focus on small molecules differentiates vTv Therapeutics, and we are eager to partner with organizations that share our hope for TTP-RA to improve the lives of people with diabetes.”
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage.
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Forward-Looking Statement
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
When will vTv Therapeutics (VTVT) present at the EASD Annual Meeting?
What is the current development status of VTVT's cadisegliatin for type 1 diabetes?
What is TTP-RA and how is it being developed by vTv Therapeutics?
What preclinical results will be presented for VTVT's TTP-RA?
